Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 circRNA vaccine
- Development stage
- Preclinical
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The NY-ESO-1 circRNA vaccine is an investigational circular RNA (circRNA)-based cancer vaccine currently in preclinical development. Developed using the proprietary 'NeoAna' circRNA synthesis platform, the vaccine consists of circular RNA encoding the NY-ESO-1 (New York esophageal squamous cell carcinoma 1) antigen, a highly immunogenic cancer-testis antigen. The circRNA is encapsulated in lipid nanoparticles (LNPs) for delivery. Unlike linear mRNA, circRNA features a covalently closed structure that provides enhanced stability and a prolonged half-life. Preclinical studies in lung cancer models have demonstrated that the vaccine promotes dendritic cell maturation, T-cell activation, and increases the CD8+/CD4+ T-cell ratio. It has also shown synergistic therapeutic potential when combined with anti-PD-1 immune checkpoint inhibitors.
- Other names
- NY-ESO-1 circular RNA vaccineNY-ESO1 circular RNA vaccineNY-ESO 1 circular RNA vaccine
02
Targets
RLR (RIG-I-like receptors)NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on NY-ESO-1 circRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 circRNA vaccine.